Evotec stock holds near $3.45 after a sharp 2026 reset
Published on 08/17/2026 at 07:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evotec stock (DE0005664809) traded at 3.446 euros on August 14, 2026, with a market value of $697.29 million and a 52-week range of 1.89 to 4.27 dollars. The latest market snapshot also showed 41,956 shares changing hands, below an average volume of 69,854 shares.
Forecasts and valuation
The same market snapshot put the consensus rating at Hold and the average price target at $3.00, with 5 analyst ratings behind it. That target sat 53.06% above the quoted $1.96 U.S. market price shown in the same data set, while the stock was down 36.4% from its start-of-year level of $3.08.
That gap matters because Evotec's valuation now depends on execution more than narrative. The market data also showed a price-to-book ratio of 0.76 and a price-to-sales ratio of 0.78, both numbers that keep the stock in deep-discount territory relative to its history.
Fresh operating picture
Recent reporting tied Evotec's second quarter and first half of 2026 to a weaker operating backdrop, and one news report said the company kept its already revised full-year outlook in place. The same report said revenue for the first half of 2026 came in at 300.1 million euros, adjusted EBITDA at negative 42.7 million euros, and the 2026 cost program Horizon aims to trim annual costs by 75 million euros by the end of 2027.
A separate market summary said management now sees 2026 revenue at 570 million to 610 million euros and EBITDA loss at up to 105 million euros. For investors, the combination of a 300.1 million-euro first half and a full-year revenue guide that tops out at 610 million euros leaves little room for a strong second-half surprise.
Partnership angle
One recent operational update centered on a collaboration with Odyssey Therapeutics for AI-enabled research and development in autoimmune and inflammatory diseases. In practical terms, that keeps Evotec's partnership model visible, but the next proof point remains whether deal flow can offset a first-half adjusted EBITDA loss of 42.7 million euros.
Evotec's business still rests on drug discovery partnerships, preclinical services, and milestone-driven collaborations, with its own pipeline layered on top. That mix can help smooth revenue, but the 2026 numbers show how quickly execution on partnership timing and cost control can move the earnings picture.
Product focus
Evotec's discovery platforms span target identification, high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design. Those capabilities are the core of the company's commercial model and the backdrop for the Odyssey Therapeutics collaboration.
Share level
At the latest quoted level, Evotec stock stood at 3.446 euros on August 14, 2026, after a 2.32% daily decline in the German market data. The U.S.-listed quote in the same market snapshot showed $1.96 at 4:00 p.m. Eastern on August 14, 2026.
Fact box
Company: Evotec SE
ISIN: DE0005664809
Ticker: EVO
Exchange: NASDAQ / Xetra
Price (as of August 14, 2026, 4:00 p.m. ET): $1.96 USD
Market cap: $697.29 million
Sector / Industry: Healthcare / Life Sciences Tools & Services
